The Neoadjuvant Paradigm for Development of Systemic Therapy and Precision Medicine for Bladder Cancer
- PMID: 26414768
- DOI: 10.1016/j.eururo.2015.09.018
The Neoadjuvant Paradigm for Development of Systemic Therapy and Precision Medicine for Bladder Cancer
Comment on
-
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.Eur Urol. 2016 May;69(5):855-62. doi: 10.1016/j.eururo.2015.08.034. Epub 2015 Sep 3. Eur Urol. 2016. PMID: 26343003 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources